BioSig Technologies
264 articles about BioSig Technologies
-
BioSig Issues April 2020 Shareholder Update Letter
4/17/2020
Information on the progress of our subsidiary ViralClear Pharmaceuticals and Vicromax(tm) – a broad-spectrum orally administered anti-viral candidate for COVID-19 Upon receipt of FDA approval, Phase II clinical trial is planned to be conducted at Mayo Clinic and is set to commence within the next several weeks under the leadership of Andrew D. Badley, M.D., Chair of the COVID-19 Task Force Update on the PURE EP(tm) System comme
-
Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax™
4/16/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) today announced that its subsidiary ViralClear Pharmaceuticals, Inc. updated its clinical development program for Vicromax™ (merimepodib, or MMPD) as a treatment for COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
-
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
4/9/2020
Vicromax shown to decrease viral production of Covid -19 coronavirus by over 98% Article highlights recent work done in laboratory studies of Covid -19 with Vicromax(tm) at the Galveston Lational Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announce
-
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
4/3/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it intends to provide a public business update via teleconference regarding its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm)
-
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19
3/31/2020
BioSig Technologies, Inc. announced that it appointed Jerome Zeldis, M.D., Ph.D as Executive Chair of ViralClear Pharmaceuticals, Inc., a new division within its majority-owned subsidiary NeuroClear Technologies, Inc., which recently acquired the rights to develop a novel pharmaceutical to treat Coronavirus Disease 2019.
-
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
3/25/2020
Novel pharmaceutical Vicromax(tm)* has already undergone extensive animal testing and human clinical experience in other indications
-
Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board One of the nation’s leading cardiologists and Medical Director of UHealth Cardiology to advise on clinical practices
3/10/2020
BioSig Technologies, Inc. announced that Zachariah P. Zachariah, M.D., a Florida-based cardiologist, joined the Advisory Board of the Company..
-
BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic NeuromodulationNew research project to focus on development of technological solutions for sympathetic nervous system disease
3/4/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company signed a new consulting agreement with John W. Osborn, Ph.D, Professor,
-
BioSig to Webcast its Presentation at the Cowen and Company’s 40th Annual Health Care Conference
3/3/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be presenting at the Cowen and Company’s 40th Annual Health Care Conference.
-
BioSig to Present at the Cowen & Co. 40th Annual Health Care
2/26/2020
Westport, CT, Feb. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be presenting at the Cowen & Co. 40th Annual Health Care Conference. The Conference is being held on March 2-4, 2020 at the Boston Marriott Copl
-
BioSig Announces Closing of Public Offering of Common Stock
2/25/2020
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the closing and funding of its previously announced “best efforts” underwritten offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share
-
BioSig Announces $10 Million Public Offering of Common Stock
2/21/2020
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has agreed to sell 2,500,000 shares of its common stock, $0.001 par value per share, in a “best efforts” underwritten offering for gross proceeds of $10 million.
-
BioSig Announces Proposed Public Offering of Common Stock
2/20/2020
Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it intends to offer shares of its common stock in a “best efforts” underwritten public offering. The offering is subject to market and other conditions and there ca
-
BioSig Completes 100th Patient Case with PURE EP(TM) System
2/19/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company successfully completed 100 patient cases with its PURE EP(tm) System.
-
BioSig to Present at the 25th Annual International AF SymposiumPURE EP(tm) System to be highlighted in a Spotlight session by Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute
1/21/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be exhibiting at the 25th Annual International AF Symposium on January 23-25, 2020 at Gaylord National Hotel in Washington, DC.
-
BioSig to Commence Patient Cases at Mayo ClinicSecond institution to begin patient enrollments with PURE EP(TM) System
1/16/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EP(tm) System at Mayo Clinic in Florida.
-
BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System
1/14/2020
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office allowed a fifth utility patent covering its PURE EPTM System.
-
BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare
12/3/2019
The Company partners with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private sector
-
BioSig Commences Clinical Trial Enrollment for PURE EP System
11/21/2019
BioSig Technologies, Inc. announced that the Company commenced its first clinical trial for its PURE EP™ System.